- Valoctocogene Roxaparvovec (BMN 270): gene therapy designed for the treatment of Hemophilia A in development by BioMarin.
SPK-8011: for Hemophilia A
- Fidanacogene elaparvovec, previously SPK-9001: an investigational bio-engineered AAV vector utilizing a high-activity factor IX transgene currently in development by Spark Therapeutics/Pfizer.
Make Informed Investment Decisions with Affordable Access to Experts
Exploring gene therapy treatments in the hemophilia space including those from BioMarin and Spark TherapeuticsTicker(s): BMRN, ONCE, PFE
Institution: University of Southern California
- Director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at USC & Chair of the Scientific and Standardization Committee on Factor VIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasis.
- Currently manages 320 patients with hemophilia A and B
- Research activities encompass clinical trials in hemophilia, the use of novel anticoagulants in children, and the development of the global hemostasis assays to monitor the effects of medications used to treat bleeding in hemophilia.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.